Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mild Autonomous Cortisol Secretion (MACS): full-pipeline trial registry
2 of 3 indexed Mild Autonomous Cortisol Secretion (MACS) trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Mild Autonomous Cortisol Secretion (MACS): 3 US clinical trials tracked, 2 recruiting.
Mild Autonomous Cortisol Secretion (MACS) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is The Cleveland Clinic, running 1 of these trials.
Enrollment posture brief
Registry condition mild-autonomous-cortisol-secretion-macs
OPEN 2 | RECR 67% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Mild Autonomous Cortisol Secretion (MACS) lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mild Autonomous Cortisol Secretion (MACS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mild Autonomous Cortisol Secretion (MACS) is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma
The Cleveland Clinic
NCT06344143
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Johns Hopkins University
NCT07247058
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Mayo Clinic
NCT06106295
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Mild Autonomous Cortisol Secretion (MACS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mild Autonomous Cortisol Secretion (MACS) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mild Autonomous Cortisol Secretion (MACS) page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Mild Autonomous Cortisol Secretion (MACS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- The Cleveland Clinic sponsors the most Mild Autonomous Cortisol Secretion (MACS) trials on record, review their full trial history before evaluating a specific study. See The Cleveland Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mild Autonomous Cortisol Secretion (MACS) condition card totals 3 registered trials; most-linked intervention Metyrapone; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.